These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30369062)

  • 1. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks.
    Amarakoon S; Martinez-Ciriano JP; van den Born LI; Baarsma S; Missotten T
    Acta Ophthalmol; 2019 Feb; 97(1):107-112. PubMed ID: 30369062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks.
    Lushchyk T; Amarakoon S; Martinez-Ciriano JP; van den Born LI; Baarsma GS; Missotten T
    Acta Ophthalmol; 2013 Sep; 91(6):e456-61. PubMed ID: 23773796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
    Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
    Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
    Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Jaffe GJ; Eliott D; Wells JA; Prenner JL; Papp A; Patel S
    Ophthalmology; 2016 Jan; 123(1):78-85. PubMed ID: 26499921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X; Hu Y; Sun X; Zhang J; Zhang M;
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV; Steén B; Seregard S; Kvanta A
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
    Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J;
    Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
    Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
    Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents.
    Enders P; Sitnilska V; Altay L; Fauser S
    Ophthalmologica; 2018; 239(1):45-51. PubMed ID: 28950272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
    Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
    Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration.
    Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2016 Aug; 30(4):265-71. PubMed ID: 27478353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
    Bakri SJ; Couch SM; McCannel CA; Edwards AO
    Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.